List of selected abstracts and publications on our compounds; other references available upon request. XY2405 A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. Marmarou A, Guy M, Murphey L, Roy F, Layani L, Combal JP, Marquer C; American Brain Injury Consortium. J. Neurotrauma. 2005; 22(12):1444-55. XY4083 Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE,  K.W. Gee PNAS 2007; 104 (19): 8059-64. A selective α7 nicotinic receptor positive allosteric modulator improves cognitive performance in rodents.  R.S. Broide, H.J. Ng, E.R. Whittemore, M.B. Tran, D.J. Hogenkamp, T.B. Johnstone, K.W. Gee.